Surrozen Confirms Common Stock, Warrants Listed on Nasdaq Capital Market

TL;DR

**SRZN confirms its common stock and warrants are still listed on Nasdaq.**

AI Summary

Surrozen, Inc. (SRZN) filed an 8-K on January 18, 2024, to update its registered securities on The Nasdaq Capital Market. The filing confirms that both its Common Stock ($0.0001 par value per share) and Redeemable Warrants (SRZNW), each exercisable for one share of Common Stock, are registered and trading. This matters to investors because it reaffirms the company's compliance with listing requirements and the continued liquidity of its securities on a major exchange, which is fundamental for trading and valuation.

Why It Matters

This filing confirms Surrozen's continued listing on The Nasdaq Capital Market, ensuring its shares and warrants remain publicly tradable and accessible to investors.

Risk Assessment

Risk Level: low — This filing is a routine update confirming existing security listings and does not introduce new financial or operational risks.

Analyst Insight

This filing is a routine compliance update; investors should focus on Surrozen's operational performance and financial results for investment decisions rather than this administrative filing.

Key Numbers

• $0.0001 — par value per share (the stated par value of Surrozen's Common Stock)

Key Players & Entities

• Surrozen, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Capital Market (company) — the exchange where Surrozen's securities are registered
• $0.0001 (dollar_amount) — par value per share of Common Stock
• SRZN (company) — trading symbol for Common Stock
• SRZNW (company) — trading symbol for Redeemable Warrants

Forward-Looking Statements

• Surrozen, Inc. will continue to maintain its listing on The Nasdaq Capital Market. (Surrozen, Inc.) — high confidence, target: 2025-01-18

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SRZN The Nasdaq

Filing Documents

• srzn-20240118.htm (8-K) — 44KB
• 0000950170-24-005198.txt ( ) — 191KB
• srzn-20240118.xsd (EX-101.SCH) — 45KB
• srzn-20240118_htm.xml (XML) — 6KB

01. Other Events

Item 8.01. Other Events. On January 18, 2024, Surrozen, Inc. issued a press release providing a business update regarding our research and development pipeline updates. The enrollment for the SZN-043 Phase 1a clinical trial in patients with chronic liver disease and healthy volunteers is complete. Surrozen expects to release safety and pharmacodynamic data in Q1 2024. In addition, Surrozen anticipates initiating enrollment in the Phase 1b portion of the study in patients with alcohol-associated hepatitis soon with proof-of-concept data from the study potentially available in the second half of 2024. Following the completion of the Phase 1 single ascending dose clinical trial for SZN-1326, Surrozen will discontinue development of SZN-1326 in inflammatory bowel disease (IBD). The decision was based on the challenges of identifying a safe and potentially effective dose along with strategic considerations including the significant clinical development expenses and market competition in IBD. SZN-1326 has been evaluated in a Phase 1 single ascending dose clinical trial in 37 healthy volunteers in doses ranging from 0.01mg to 25mg. Several subjects at higher dose levels experienced asymptomatic liver transaminase elevations, including four subjects with grade 3 ALT and AST elevations. Surrozen previously reported that 3 of these 4 subjects had grade 3 ALT and AST elevations in 2022. No other clinically significant laboratory abnormalities were observed, and the transaminase elevations resolved spontaneously in all subjects. No serious adverse events were observed during the study. While no safety signal was observed at lower doses, lower dose levels would not be expected to activate Wnt signaling and produce a pharmacologic effect in the intestine.

Forward Looking Statements

Forward Looking Statements This current report contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates SZN-043, and SZN-413 (including anticipated clinical development timelines and the availability of data, the potential for such product candidates to be used to treat human disease), the potential and timeline to nominate the lead development candidate pursuant to its partnership with Boehringer Ingelheim and its expectations with respect to its cash runway. These statements are based on various assumptions, whether or not identified in this current report, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical or and clinical trials with respect to SZN-043, SZN-413 and potential future drug candidates; th

View Full Filing

View this 8-K filing on SEC EDGAR